Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

By Matina Stevis-Gridneff Reporting from Toronto After President Trump imposed tariffs on Canada on Tuesday, Prime Minister Justin Trudeau made an extraordinary statement that was largely lost in ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

German science and technology company Merck on Thursday forecast its net sales to be in the range of €21.5 billion ($23.2 ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Merck & Co has entered into a worldwide licensing deal with Opko Health’s ModeX Therapeutics unit for a vaccine candidate against Epstein-Barr virus (EBV) that could be worth up to $922.5 ...

President Donald Trump’s on-again, off-again trade war with Canada and Mexico could create a politically awkward situation (to say the least) with the United States’ neighbors when the three ...

Shares of Merck & Co. Inc. MRK slipped 1.46% to $93.35 Wednesday, on what proved to be an all-around mixed trading session ...

We are always excited about a new PowerToys utility/feature upgrade, and this time it’s related to the Run utility. After recently adding video transcoding capabilities in the app, Microsoft ...